Arete Wealth Advisors LLC lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 8.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,910 shares of the financial services provider’s stock after selling 179 shares during the quarter. Arete Wealth Advisors LLC’s holdings in iShares Biotechnology ETF were worth $277,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of iShares Biotechnology ETF by 29.3% during the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after acquiring an additional 538,899 shares during the period. Commerce Bank lifted its stake in shares of iShares Biotechnology ETF by 1.8% during the third quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock valued at $108,234,000 after acquiring an additional 12,921 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after acquiring an additional 164,000 shares during the period. Main Management ETF Advisors LLC lifted its stake in shares of iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after acquiring an additional 14,535 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in shares of iShares Biotechnology ETF by 24.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after acquiring an additional 42,822 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Down 0.8 %
Shares of IBB opened at $136.61 on Friday. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57. The stock’s fifty day simple moving average is $141.84 and its 200-day simple moving average is $142.25.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- When to Sell a Stock for Profit or Loss
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Comparing and Trading High PE Ratio Stocks
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What Are Dividends? Buy the Best Dividend Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.